Beyond the Static Document: Why Evidence-Driven TPP Optimization Is Becoming a Strategic Imperative in Pharma
Every drug development program starts with a hypothesis about the product it hopes to become. The Target Product Profile (TPP) is where that hypothesis is written down: the intended indication, the ef ...
Trends in HEOR: What Payers and HTA Bodies Are Asking for Now
A therapy can clear every regulatory hurdle and still face difficult questions at the formulary or reimbursement stage. That gap between regulatory approval and patient access is where health economic ...
A Budget Impact Analysis Payers Can Trust: The Thelansis Framework
How the Thelansis budget impact modeling framework turns a payer's first and most literal question, "What will this cost my budget next year?" into a forecast a client can act on and a payer can indep ...
Defining a Differentiated Target Product Profile (TPP) to Win in a Crowded Therapy Area
Background: The client was advancing a Phase II biologic in a chronic inflammatory disease category already dense with competition. While early clinical data showed encouraging efficacy and a managea ...
Can Premium Pricing Survive in Rare Diseases? What 2026 Signals Say
For nearly two decades, rare diseases have lived in a pricing exception zone. Small patient populations, high unmet need, limited competition, and outcomes that could genuinely change a patient's life ...
Epilansis: A NextGen, Cloud-based Epidemiology Platform for Faster, Smarter Market Decisions
With the healthcare landscape shifting rapidly, teams across biopharma, consulting, med-tech, and healthcare strategy face a common bottleneck: turning scattered epidemiology data, literature, real wo ...